ACTUATE THERAPEUTICS, INC. 8-K

What Happened Actuate Therapeutics, Inc. (ACTU) filed an 8-K reporting that on July 15, 2026 it received a Nasdaq notice saying its Market Value of Listed Securities (MVLS) was below the $50 million minimum required for the Nasdaq Global Market. Nasdaq’s staff found the MVLS deficiency for the period June 1, 2026 through July 14, 2026. The notice does not have any immediate effect on the listing — ACTU shares continue trading on Nasdaq under the symbol “ACTU.”

Key Details

• Notice received: July 15, 2026; deficiency period: June 1–July 14, 2026.
• Minimum required MVLS: $50 million (Nasdaq Listing Rule 5450(b)(2)(A)).
• Compliance deadline: 180 days from the notice, through January 11, 2027; to regain compliance the MVLS must close at $50M+ for at least 10 consecutive business days.
• If it fails to regain compliance, Nasdaq would notify the company that its securities are subject to delisting; Actuate may appeal or seek transfer to the Nasdaq Capital Market.

Why It Matters This filing signals a formal risk that Actuate could be moved off the Nasdaq Global Market if it does not restore its MVLS to the required level by January 11, 2027. Delisting or a transfer to a different market tier could affect liquidity, investor access and perceptions of the stock. The company says it will monitor MVLS and pursue reasonable measures to regain compliance but makes no guarantee it will succeed.